PT  - JOURNAL ARTICLE
AU  - Mufti, Kheireddin
AU  - Yu, Eric
AU  - Rudakou, Uladzislau
AU  - Krohn, Lynne
AU  - Ruskey, Jennifer A.
AU  - Asayesh, Farnaz
AU  - Laurent, Sandra B.
AU  - Spiegelman, Dan
AU  - Arnulf, Isabelle
AU  - Hu, Michele T.M.
AU  - Montplaisir, Jacques Y.
AU  - Gagnon, Jean-François
AU  - Desautels, Alex
AU  - Dauvilliers, Yves
AU  - Gigli, Gian Luigi
AU  - Valente, Mariarosaria
AU  - Janes, Francesco
AU  - Bernardini, Andrea
AU  - Högl, Birgit
AU  - Stefani, Ambra
AU  - Holzknecht, Evi
AU  - Sonka, Karel
AU  - Kemlink, David
AU  - Oertel, Wolfgang
AU  - Janzen, Annette
AU  - Plazzi, Giuseppe
AU  - Antelmi, Elena
AU  - Figorilli, Michela
AU  - Puligheddu, Monica
AU  - Mollenhauer, Brit
AU  - Trenkwalder, Claudia
AU  - Sixel-Döring, Friederike
AU  - De Cock, Valérie Cochen
AU  - Monaca, Christelle Charley
AU  - Heidbreder, Anna
AU  - Ferini-Strambi, Luigi
AU  - Dijkstra, Femke
AU  - Viaene, Mineke
AU  - Abril, Beatriz
AU  - Boeve, Bradley F.
AU  - Trempe, Jean-François
AU  - Rouleau, Guy A.
AU  - Postuma, Ronald B.
AU  - Gan-Or, Ziv
TI  - Novel associations of <em>BST1</em> and <em>LAMP3</em> with rapid eye movement sleep behavior disorder
AID  - 10.1101/2020.06.27.20140350
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.27.20140350
4099  - http://medrxiv.org/content/early/2020/06/28/2020.06.27.20140350.short
4100  - http://medrxiv.org/content/early/2020/06/28/2020.06.27.20140350.full
AB  - Isolated rapid-eye-movement (REM) sleep behavior disorder (iRBD) is a parasomnia, characterized by loss of muscle atonia and dream enactment occurring during REM sleep phase. Since a large subgroup of iRBD patients will convert to Parkinson’s disease, and since previous genetic studies have suggested common genes, it is likely that there is at least a partial overlap between iRBD and Parkinson’s disease genetics. To further examine this potential overlap and to identify genes specifically involved in iRBD, we fully sequenced 25 genes previously identified in genome-wide association studies of Parkinson’s disease. The genes were captured and sequenced using targeted next-generation sequencing in a total of 1,039 iRBD patients and 1,852 controls of European ancestry. The role of rare heterozygous variants in these genes was examined using burden tests and optimized sequence Kernel association tests (SKAT-O), adjusted for age and sex. The contribution of biallelic (homozygous and compound heterozygous) variants was further tested in all genes. To examine the association of common variants in the target genes, we used logistic regression adjusted for age and sex. We found a significant association between rare heterozygous nonsynonymous variants in BST1 and iRBD (p=0.0003 at coverage >50X and 0.0004 at >30X), mainly driven by three nonsynonymous variants (p.V85M, p.I101V and p.V272M) found in a total of 22 (1.2%) controls vs. two (0.2%) patients. Rare non-coding heterozygous variants in LAMP3 were also found to be associated with reduced iRBD risk (p=0.0006 at >30X). We found no statistically significant association between rare heterozygous variants in the rest of genes and risk of iRBD. Several carriers of biallelic variants were identified, yet there was no overrepresentation in iRBD patients vs. controls. To examine the potential impact of the rare nonsynonymous BST1 variants on the protein structure, we performed in silico structural analysis. All three variants seem to be loss-of-function variants significantly affecting the protein structure and stability. Our results suggest that rare coding variants in BST1 and rare non-coding variants in LAMP3 are associated with iRBD, and additional studies are required to replicate these results and examine whether loss-of-function of BST1 could be a therapeutic target.Competing Interest StatementJYM received fees from Takeda, Eisai and Paladin Pharma for consultancies in unrelated fields. ZGO received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Inceptions Sciences (now Ventus), Ono Therapeutics, Denali, Deerfield, Neuron23 and Handl Therapeutics. None of these companies were involved in any parts of preparing, drafting and publishing this review.Funding StatementThis work was financially supported by the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), Parkinson Canada the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives (HBHL) program. The Montreal cohort was funded by the Canadian Institutes of Health Research (CIHR) and the W. Garfield Weston Foundation. The Oxford Discovery study is funded by the Monument Trust Discovery Award from Parkinson UK and supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford, the NIHR Clinical Research Network and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study participants signed an informed consent form before entering the study, and the study protocol was approved by the institutional review board of McGill University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for the analysis is available in the supplementary tables. Anonymized raw data will be shared upon request from any qualified investigator.AAOage at onsetAASage at samplingCADDCombined Annotation Dependent DepletionCIconfidence intervalDOCdepth of coverageF_Afrequency in affectedF_Cfrequency in controlGATKGenome Analysis ToolkitGnomADGenome Aggregation DatabaseGTExGenotype-tissue expressionGWASgenome-wide association studyhg19human genome version 19iRBDisolated rapid-eye-movement sleep behavior disorderLDlinkage disequilibriumLOFloss-of-functionMAFminor allele frequencyMIPsmolecular inversion probesNGSnext-generation sequencingNSnon-synonymousORodds ratioPCAprinciple component analysisQCquality controlQsquality scoreREMrapid eye movementSKATsequence kernel association testSKAT-Ooptimized SKATUTRuntranslated regionvPSGvideo polysomnography